BEOVU 120mg/ml solution for injection in pre-filled syringe EUROPHARM ORIGINAL MEDICINE
Chemical substance: brolucizumab
ATC code: S01LA06 • Sensory organs | Ocular vascular disorder agents | Antineovascularisation agents
Active substance
Results for the substance brolucizumab
1 result
About this active substance
Brolucizumab is a medication used for the treatment of neovascular (wet) age-related macular degeneration (AMD). It is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), reducing the formation of abnormal blood vessels and fluid accumulation in the retina.
The medication is administered via intravitreal injection, usually once every few months, as directed by a doctor. The treatment requires regular monitoring to assess the patient's response and prevent complications.
Common side effects include eye pain, redness, inflammation, and increased intraocular pressure. In rare cases, more severe adverse effects such as endophthalmitis or retinal detachment may occur.
Brolucizumab is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about any other eye conditions or ongoing treatments.
The medication is administered via intravitreal injection, usually once every few months, as directed by a doctor. The treatment requires regular monitoring to assess the patient's response and prevent complications.
Common side effects include eye pain, redness, inflammation, and increased intraocular pressure. In rare cases, more severe adverse effects such as endophthalmitis or retinal detachment may occur.
Brolucizumab is not recommended for pregnant or breastfeeding women unless the benefits outweigh the risks. Patients should inform their doctor about any other eye conditions or ongoing treatments.